Northwest Biotherapeutics (NWBO) Net Margin (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Net Margin of 688.26% for Q1 2026, up 454054.0% year-over-year from N/an in Q1 2025, and down 469.71% quarter-over-quarter from 186.16% in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Net Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 688.26% for Q1 2026.
- In Q1 2026, Net Margin rose 454054.0% year-over-year to 688.26%; the TTM figure through Mar 2026 stood at 3023.98% (up 280901.0% YoY), while the FY2025 annual figure was 4461.32%, up 170308.0% from the prior year.
- Net Margin for Q1 2026 stood at 688.26%, down from 186.16% in the prior quarter.
- The five-year high for Net Margin was 186.16% in Q4 2025, with the low at 15947.57% in Q3 2022.
- The 5-year median for Net Margin is 5463.87% (2024), against an average of 6341.24%.
- The sharpest annual moves came in 2022 and 2025: Net Margin plunged 1720757 bps in 2022, then surged 1252209 bps in 2025.
- Northwest Biotherapeutics' Net Margin stood at 4740.03% in 2022, then surged by 32 bps to 3217.53% in 2023, then tumbled by 283 bps to 12335.93% in 2024, then jumped by 102 bps to 186.16% in 2025, then tumbled by 470 bps to 688.26% in 2026.
- Business Quant data shows NWBO's Net Margin at 688.26% in Q1 2026, 186.16% in Q4 2025, and 13591.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -1,183.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,183.77% |
| Mar 31, 2026 | -688.26% |
| Dec 31, 2025 | 186.16% |
| Sep 30, 2025 | -13,591.00% |
| Jun 30, 2025 | -12,166.41% |
| Mar 31, 2025 | -5,228.80% |
| Dec 31, 2024 | -12,335.93% |
| Sep 30, 2024 | -5,463.87% |
| Jun 30, 2024 | -3,590.20% |
| Mar 31, 2024 | -6,647.89% |
| Dec 31, 2023 | -3,217.53% |
| Sep 30, 2023 | -5,921.43% |
| Jun 30, 2023 | -7,446.27% |
| Mar 31, 2023 | -1,255.34% |
| Dec 31, 2022 | -4,740.03% |
| Sep 30, 2022 | -15,947.57% |
| Jun 30, 2022 | -6,219.71% |
| Mar 31, 2022 | -3,527.05% |
| Sep 30, 2021 | 1,260.00% |
| Jun 30, 2021 | 1,060.10% |